Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: An international collaborative study

Leukemia

Volumn 30, Issue 1, 2016, Pages 32-38

  Boer, J M ^a   Van Der Veer, A ^a   Rizopoulos, D ^b   Fiocco, M ^c,d   Sonneveld, E ^c   De Groot Kruseman, H A ^c   Kuiper, R P ^e   Hoogerbrugge, P ^c,f   Horstmann, M ^g   Zaliova, M ^h,i   Palmi, C ^j   Trka, J ⁱ   Fronkova, E ⁱ   Emerenciano, M ^k   Do Socorro Pombo De Oliveira, M ^k   Mlynarski, W ^l   Szczepanski, T ^m   Nebral, K ⁿ   Attarbaschi, A ⁿ   Venn, N ^o   Sutton, R ^o   Schwab, C J ^p   Enshaei, A ^p   Vora, A ^q   Stanulla, M ^r   Schrappe, M ^h   Cazzaniga, G ^j   Conter, V ^j   Zimmermann, M ^r   Moorman, A V ^p   Pieters, R ^a,c,f   Den Boer, M L ^a,c   more..

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c DCOG   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Department of Radiation Oncology   (Netherlands)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j UNIVERSITY OF MILANO BICOCCA   (Italy)

^k INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^l MEDICAL UNIVERSITY OF LODZ   (Poland)

^m MEDICAL UNIVERSITY OF SILESIA   (Poland)

ⁿ ST ANNA CHILDREN S HOSPITAL   (Austria)

^o CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^p NEWCASTLE UNIVERSITY   (United Kingdom)

^q SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^r HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GENOMIC DNA; IKAROS TRANSCRIPTION FACTOR; IKZF1 PROTEIN, HUMAN; ONCOPROTEIN; TEL-AML1 FUSION PROTEIN; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; EVENT FREE SURVIVAL; GENE; GENE DELETION; GENETIC ASSOCIATION; HUMAN; IKZF1 GENE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ADOLESCENT; ADULT; CHILD; GENETICS; INFANT; INTERNATIONAL COOPERATION; MORTALITY; PRESCHOOL CHILD; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CORE BINDING FACTOR ALPHA 2 SUBUNIT; GENE DELETION; HUMANS; IKAROS TRANSCRIPTION FACTOR; INFANT; INTERNATIONAL COOPERATION; ONCOGENE PROTEINS, FUSION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84953355882     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.199     Document Type: Article

References (44)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
2. Moricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H et al. Longterm results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010; 24: 265-284.
3. Waanders E, van der Velden VH, van der Schoot CE, van Leeuwen FN, van Reijmersdal SV, de Haas V et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia 2011; 25: 254-258.
4. van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013; 122: 2622-2629.
5. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-480.
6. Kuiper RP, Waanders E, van der Velden VH, van Reijmersdal SV, Venkatachalam R, Scheijen B et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010; 24: 1258-1264.
7. Dorge P, Meissner B, Zimmermann M, Moricke A, Schrauder A, Bouquin JP et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 2013; 98: 428-432.
8. Yang YL, Hung CC, Chen JS, Lin KH, Jou ST, Hsiao CC et al. IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan. Cancer Sci 2011; 102: 1874-1881.
9. Volejnikova J, Mejstrikova E, Dorge P, Meissner B, Zimmermannova O, Svojgr K et al. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia. Pediatr Blood Cancer 2013; 60: 420-427.
10. Olsson L, Ivanov Ofverholm I, Noren-Nystrom U, Zachariadis V, Nordlund J, Sjogren H et al. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013. Br J Haematol 2015; e-pub ahead of print 27 May 2015; doi:10.1111/bjh.13514.
11. Clappier E, Grardel N, Bakkus M, Rapion J, De Moerloose B, Kastner P et al. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951. Leukemia 2015; 29: 2154-2161.
12. Kaufmann C, Yoshida T, Perotti EA, Landhuis E, Wu P, Georgopoulos K. A complex network of regulatory elements in Ikaros and their activity during hemo-lymphopoiesis. EMBO J 2003; 22: 2211-2223.
13. Georgopoulos K, Bigby M, Wang JH, Molnar A, Wu P, Winandy S et al. The Ikaros gene is required for the development of all lymphoid lineages. Cell 1994; 79: 143-156.
14. Yoshida T, Landhuis E, Dose M, Hazan I, Zhang J, Naito T et al. Transcriptional regulation of the Ikzf1 locus. Blood 2013; 122: 3149-3159.
15. Yoshida T, Georgopoulos K. Ikaros fingers on lymphocyte differentiation. Int J Hematol 2014; 100: 220-229.
16. Ferreiros-Vidal I, Carroll T, Taylor B, Terry A, Liang Z, Bruno L et al. Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation. Blood 2013; 121: 1769-1782.
17. Sun L, Liu A, Georgopoulos K. Zinc finger-mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development. EMBO J 1996; 15: 5358-5369.
18. Schjerven H, McLaughlin J, Arenzana TL, Frietze S, Cheng D, Wadsworth SE et al. Selective regulation of lymphopoiesis and leukemogenesis by individual zinc fingers of Ikaros. Nat Immunol 2013; 14: 1073-1083.
19. Bottardi S, Mavoungou L, Bourgoin V, Mashtalir N, Affar el B, Milot E. Direct protein interactions are responsible for Ikaros-GATA and Ikaros-Cdk9 cooperativeness in hematopoietic cells. Mol Cell Biol 2013; 33: 3064-3076.
20. Tokunaga K, Yamaguchi S, Iwanaga E, Nanri T, Shimomura T, Suzushima H et al. High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia. Eur J Haematol 2013; 91: 201-208.
21. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453: 110-114.
22. van der Veer A, Zaliova M, Mottadelli F, De Lorenzo P, Te Kronnie G, Harrison CJ et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 2014; 123: 1691-1698.
23. Palmi C, Valsecchi MG, Longinotti G, Silvestri D, Carrino V, Conter V et al. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia Haematologica 2013; 98: 1226-1231.
24. Sun L, Heerema N, Crotty L, Wu X, Navara C, Vassilev A et al. Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1999; 96: 680-685.
25. Suzuki K, Ono R, Ohishi K, Masuya M, Kataoka I, Liu B et al. IKAROS isoform 6 enhances BCR-ABL1-mediated proliferation of human CD34+ hematopoietic cells on stromal cells. Int J Oncol 2012; 40: 53-62.
26. Nishii K, Katayama N, Miwa H, Shikami M, Usui E, Masuya M et al. Non-DNAbinding Ikaros isoform gene expressed in adult B-precursor acute lymphoblastic leukemia. Leukemia 2002; 16: 1285-1292.
27. Klein F, Feldhahn N, Herzog S, Sprangers M, Mooster JL, Jumaa H et al. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene 2006; 25: 1118-1124.
28. Dupuis A, Gaub MP, Legrain M, Drenou B, Mauvieux L, Lutz P et al. Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations. Leukemia 2013; 27: 503-507.
29. Caye A, Beldjord K, Mass-Malo K, Drunat S, Soulier J, Gandemer V et al. Breakpointspecific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. Haematologica 2013; 98: 597-601.
30. Palmi C, Lana T, Silvestri D, Savino A, Kronnie GT, Conter V et al. Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia". Haematologica 2013; 98: e164-e165.
31. Mi JQ, Wang X, Yao Y, Lu HJ, Jiang XX, Zhou JF et al. Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases. Leukemia 2012; 26: 1507-1516.
32. Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model. Springer-Verlag: New York, chapter 8: 2000.
33. Schwickert TA, Tagoh H, Gultekin S, Dakic A, Axelsson E, Minnich M et al. Stage-specific control of early B cell development by the transcription factor Ikaros. Nat Immunol 2014; 15: 283-293.
34. Joshi I, Yoshida T, Jena N, Qi X, Zhang J, Van Etten RA et al. Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. Nat Immunol 2014; 15: 294-304.
35. Enshaei A, Schwab CJ, Konn ZJ, Mitchell CD, Kinsey SE, Wade R et al. Long-term follow-up of ETV6-RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor. Leukemia 2013; 27: 2256-2259.
36. Clappier E, Auclerc MF, Rapion J, Bakkus M, Caye A, Khemiri A et al. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia 2014; 28: 70-77.
37. Zaliova M, Zimmermannova O, Dorge P, Eckert C, Moricke A, Zimmermann M et al. ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia. Leukemia 2014; 28: 182-185.
38. Payne KJ, Nicolas J-H, Zhu JY, Barsky LW, Crooks GM. Cutting edge: predominant expression of a novel Ikaros isoform in normal human hemopoiesis. J Immunol 2001; 167: 1867-1870.
39. Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, Soverini S et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 2009; 114: 2159-2167.
40. Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J et al. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet 2014; 46: 116-125.
41. Olsson L, Albitar F, Castor A, Behrendtz M, Biloglav A, Paulsson K et al. Cooperative genetic changes in pediatric B-cell precursor acute lymphoblastic leukemia with deletions or mutations of IKZF1. Genes Chromosomes Cancer 2015; 54: 315-325.
42. Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH et al. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia 2013; 27: 1497-1503.
43. Churchman M, Low J, Payne-Turner D, Chen S-C, Ma J, Althoff MJ et al. High content screening identifies synthetic lethality of retinoid receptor agonists in IKZF1-mutated BCR-ABL1 positive acute lymphoblastic leukemia. Blood 2013; 122: 172.
44. Papathanasiou P, Attema JL, Karsunky H, Hosen N, Sontani Y, Hoyne GF et al. Selfrenewal of the long-term reconstituting subset of hematopoietic stem cells is regulated by Ikaros. Stem Cells 2009; 27: 3082-3092.